fig6

Fibroblast growth factor receptor alterations and resistance mechanisms in the treatment of pediatric solid tumors

Figure 6. Association of pediatric patient outcomes with FGFR gene family expression levels. Using the Kocak dataset from the R2 Genomics Analysis and Visualization Platform[19] (http://r2.amc.nl; accessed on 10/15/2024), Kaplan-Meier curves were generated and downloaded depicting overall survival (OS) among all neuroblastoma patients, separated by tumors with high expression (in red) vs. low expression (in blue) of FGFR1 (A); FGFR2 (B); FGFR3 (C); and FGFR4 (D), with patient numbers in parentheses. Using the Williamson and Dirksen datasets[20,21] from the R2 Genomics Analysis and Visualization Platform (http://r2.amc.nl; accessed on 10/16/2024), Kaplan-Meier curves were generated and downloaded depicting overall survival (OS) among all with rhabdomyosarcoma (E-H) and Ewing sarcoma (I-L), separated by tumors with high expression (in red) vs. low expression (in blue) of FGFR1 (E,I), FGFR2 (F,J), FGFR3 (G,K), and FGFR4 (H,L), with patient numbers in parentheses. FGFR: fibroblast growth factor receptor.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/